Kevin K Brown,1 Simon LF Walsh,2 Anand Devaraj,3 Jin Woo Song,4 Wim A Wuyts,5 Claudia Valenzuela,6 Rainer-Georg Goeldner,7 Susanne Stowasser,8 Rozsa Schlenker-Herceg,9 Athol U Wells10 on behalf of the INBUILD trial investigators
1Department of Medicine, National Jewish Health, Denver, CO, USA; 2National Heart and Lung Institute, Imperial College, London, UK; 3Department of Radiology, Royal Brompton and Harefield NHS Foundation Trust, London, UK; 4University of Ulsan College of Medicine, Asan Medical Center, Pulmonary and Critical Care Medicine, Seoul, South Korea; 5Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium; 6Hospital Universitario de La Princesa, Madrid, Spain; 7Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; 8Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 10National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, UK
Introduction
- Nintedanib has been approved by the FDA for the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated ILD, and chronic fibrosing ILDs with a progressive phenotype.
- In the INBUILD trial conducted in subjects with chronic fibrosing ILDs with a progressive phenotype (other than IPF), nintedanib slowed the rate of decline in FVC versus placebo, with adverse events that were manageable for most subjects.1
- Previous studies suggested that the progression of progressive fibrosing ILDs is more rapid in subjects with a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT).2,3